/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Mahesh Parmar

MRC Clinical Trials Unit at UCL(GB)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

559

Papers

58.1K

Citations

103

h-index

295

i10-index

Mahesh Parmar is an academic researcher from MRC Clinical Trials Unit at UCL. The author has contributed to research in topics: Statistical Methods in Clinical Trials & Prostate Cancer Treatment and Research & Ovarian cancer diagnosis and treatment. The author has an h-index of 103, co-authored 476 publications.

ORCID: 0000-0003-0166-1700

Research Topics

Statistical Methods in Clinical Trials Prostate Cancer Treatment and Research Ovarian cancer diagnosis and treatment Health Systems, Economic Evaluations, Quality of Life Meta-analysis and systematic reviews

Papers by this author

works

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

2017 · The Lancet · 3,118 citations

https://doi.org/10.1016/s0140-6736(16)32401-1

Hashim U. Ahmed Ahmed El‐Shater Bosaily Louise Brown Rhian Gabe

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

2018 · The Lancet · 1,223 citations

https://doi.org/10.1016/s0140-6736(18)32486-3

Christopher Parker Nicholas D. James Chris Brawley Noel W. Clarke

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

2003 · The Lancet · 1,193 citations

https://doi.org/10.1016/s0140-6736(03)13718-x

Mahesh Parmar Jonathan A. Ledermann Nicoletta Colombo Andreas du Bois

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

2015 · The Lancet · 1,082 citations

https://doi.org/10.1016/s0140-6736(15)01224-6

Ian Jacobs Usha Menon Andy Ryan Aleksandra Gentry‐Maharaj

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

2013 · BMC Medical Research Methodology · 967 citations

https://doi.org/10.1186/1471-2288-13-152

Patrick Royston Mahesh Parmar

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

2015 · The Lancet Oncology · 845 citations

https://doi.org/10.1016/s1470-2045(15)00086-8

Amit M. Oza Adrian Cook Jacobus Pfisterer Andrew Embleton-Thirsk

Research topics

topics

Statistical Methods in Clinical Trials

Prostate Cancer Treatment and Research

Ovarian cancer diagnosis and treatment

Health Systems, Economic Evaluations, Quality of Life

Meta-analysis and systematic reviews

Chat about Author

Papers

Chat

Click to start Chat